Summarized by Masters of Longevity from Science Daily - Health & Medicine.
A science feature that walks readers through research on a novel drug approach aimed at overcoming cancer therapy resistance, highlighting why the work matters and what questions remain.
Key Takeaways
- The compound CS18 is a TopBP1 inhibitor that enhanced PARP inhibitor activity in experimental models.
- CS18 restored sensitivity to the EGFR inhibitor osimertinib in resistant lung cancer cell lines.
- In animal studies CS18 slowed tumor growth when combined with standard therapies.
